Balyasny Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Balyasny Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-200,000	Closed	-$4.19M	–	1609
2019 Q3	$4.19M	Buy	+200,000	New	+$4.08M	0.03%	581
2018 Q4	–	Sell	-210,000	Closed	-$5.79M	–	1914
2018 Q3	$5.79M	Buy	+210,000	New	+$5.94M	0.03%	654
2018 Q2	–	Sell	-378,700	Closed	-$12.1M	–	2312
2018 Q1	$12.1M	Buy	+378,700	New	+$13.3M	0.05%	472

Balyasny Asset Management's AIMT Position: Q4 2020 in Review

Balyasny Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 388,384 shares — an estimated $13.4M sold.

Balyasny Asset Management first reported a position in AIMT in Q1 2018 and held it in 11 quarters. The position peaked at $22.8M in Q1 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Balyasny Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Balyasny Asset Management sold 388,384 Aimmune Therapeutics shares in Q4 2020, an estimated $13.4M.
Balyasny Asset Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 11 quarters.
Balyasny Asset Management's Aimmune Therapeutics position peaked at $22.8M in Q1 2018.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.